See more : Castellum AB (publ) (CWQXY) Income Statement Analysis – Financial Results
Complete financial analysis of Accelerate Diagnostics, Inc. (AXDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accelerate Diagnostics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- NVIDIA Corporation (NVD.DE) Income Statement Analysis – Financial Results
- Haier Smart Home Co., Ltd. (690D.DE) Income Statement Analysis – Financial Results
- Mesa Air Group, Inc. (MESA) Income Statement Analysis – Financial Results
- Fujian Kuncai Material Technology Co., Ltd. (603826.SS) Income Statement Analysis – Financial Results
- Wee-Cig International Corporation (WCIG) Income Statement Analysis – Financial Results
Accelerate Diagnostics, Inc. (AXDX)
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 12.75M | 11.78M | 11.17M | 9.30M | 5.67M | 4.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 475.52K | 183.13K | 212.70K | 502.11K | 118.61K | 850.57K | 653.98K | 855.66K | 1.57M | 2.90M | 7.38M | 2.50M | 2.10M |
| Cost of Revenue | 9.51M | 9.45M | 12.16M | 6.71M | 4.90M | 3.19M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.65K | 56.65K | 41.60K | 155.51K | 65.63K | 148.54K | 184.25K | 534.64K | 644.01K | 1.23M | 1.15M | 300.00K | 300.00K |
| Gross Profit | 2.55M | 3.30M | -381.00K | 4.46M | 4.40M | 2.48M | 3.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 465.87K | 126.48K | 171.10K | 346.60K | 52.98K | 702.03K | 469.73K | 321.02K | 923.38K | 1.67M | 6.23M | 2.20M | 1.80M |
| Gross Profit Ratio | 21.15% | 25.90% | -3.23% | 39.94% | 47.33% | 43.79% | 76.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 97.97% | 69.07% | 80.44% | 69.03% | 44.67% | 82.54% | 71.83% | 37.52% | 58.91% | 57.60% | 84.37% | 88.00% | 85.71% |
| Research & Development | 25.35M | 26.92M | 21.94M | 21.26M | 25.35M | 27.64M | 22.30M | 28.20M | 26.02M | 20.05M | 10.67M | 432.00K | 455.00K | 501.60K | 745.93K | 880.98K | 991.58K | 2.16M | 1.30M | 554.42K | 568.87K | 326.58K | 123.49K | 0.00 | 0.00 | 68.77K | 100.00K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 2.95M | 810.08K | 869.35K | 919.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 709.01K | 1.53M | 997.83K | 956.67K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.32K | 9.62K | 1.40K | 13.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 288.86K | 817.35K | 1.20M | 1.29M | 0.00 | 0.00 |
| SG&A | 31.23M | 39.19M | 49.24M | 46.90M | 51.89M | 55.21M | 45.06M | 36.20M | 17.88M | 10.70M | 4.31M | 2.95M | 819.70K | 870.75K | 932.99K | 1.02M | 935.67K | 903.65K | 994.98K | 978.37K | 1.19M | 742.07K | 997.87K | 2.34M | 2.20M | 2.25M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -227.00K | -20.00K | -60.00K | -14.00K | -28.00K | -184.00K | 2.35M | 1.79M | 888.00K | -4.45K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 293.11K | 490.02K | 170.38K | 638.43K | 895.80K | 0.00 | 0.00 | 200.00K | 100.00K |
| Operating Expenses | 56.58M | 66.11M | 71.18M | 68.16M | 77.23M | 82.85M | 67.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.19M | 2.24M | 3.38M | 2.61M | 1.83M | 2.25M | 1.24M | 1.76M | 3.24M | 2.20M | 2.32M | 1.40M | 600.00K |
| Cost & Expenses | 66.09M | 75.56M | 83.34M | 74.87M | 82.13M | 86.04M | 68.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.20M | 2.30M | 3.42M | 2.76M | 1.89M | 2.40M | 1.42M | 2.29M | 3.88M | 3.42M | 3.47M | 1.70M | 900.00K |
| Interest Income | 1.12M | 551.00K | 88.00K | 855.00K | 2.81M | 2.85M | 908.00K | 494.00K | 74.00K | 64.00K | 33.49K | 17.00K | 16.09K | 6.05K | 18.33K | 63.08K | 0.00 | 0.00 | 0.00 | 64.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.74M | 3.77M | 15.55M | 15.55M | 14.26M | 10.11M | 0.00 | 23.00K | 23.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.25M | 3.00M | 2.52M | 3.00M | 2.60M | 2.56M | 2.20M | 2.35M | 1.79M | 888.00K | 362.50K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 282.79K | 293.32K | 170.38K | 638.43K | 895.80K | 702.53K | 328.01K | 200.00K | 100.00K |
| EBITDA | -49.77M | -55.80M | -59.59M | -59.66M | -67.56M | -75.44M | -61.34M | -64.15M | -43.68M | -30.10M | -14.92M | -3.15M | -153.53K | 873.28K | -409.03K | -1.43M | -1.80M | -2.71M | -1.95M | -1.49M | -1.64M | -598.92K | -800.34K | -1.42M | 175.64K | 4.24M | 1.00M | 1.30M |
| EBITDA Ratio | -412.73% | -466.44% | -585.42% | -536.57% | -725.33% | -1,322.59% | -1,534.76% | -25,876.42% | -29,716.33% | -25,050.82% | -30,911.59% | -498.73% | -14.99% | 37.82% | -28.00% | -298.12% | -1,026.29% | -1,354.58% | -391.97% | -1,255.86% | -129.90% | -69.93% | 20.13% | -108.49% | 6.06% | 57.43% | 28.00% | 61.90% |
| Operating Income | -54.03M | -62.81M | -71.56M | -63.70M | -72.83M | -80.37M | -64.18M | -66.50M | -45.55M | -31.52M | -15.31M | -5.35M | -409.43K | 611.79K | -679.12K | -1.73M | -2.11M | -3.20M | -2.26M | -1.77M | -1.55M | -769.30K | -1.44M | -2.32M | -526.89K | 3.91M | 800.00K | 1.20M |
| Operating Income Ratio | -448.03% | -492.51% | -607.37% | -570.53% | -783.38% | -1,417.44% | -1,536.56% | -27,032.93% | -30,985.71% | -25,833.61% | -31,709.35% | -2,267.80% | -36.52% | 27.24% | -53.48% | -363.31% | -1,154.63% | -1,506.59% | -449.89% | -1,494.69% | -181.83% | -117.63% | -168.15% | -147.83% | -18.18% | 52.99% | 32.00% | 57.14% |
| Total Other Income/Expenses | -6.74M | 235.00K | -6.10M | -14.50M | -11.59M | -7.75M | 649.00K | 394.00K | 51.00K | -470.00K | 29.00K | 41.28K | 30.66K | 29.95K | -53.41K | 47.29K | 190.24K | 173.90K | 168.15K | 74.09K | 151.34K | 50.54K | -426.14K | 861.08K | 565.94K | 536.88K | 400.00K | -1.20M |
| Income Before Tax | -60.77M | -62.57M | -77.66M | -78.20M | -84.42M | -88.12M | -63.53M | -66.11M | -45.50M | -31.46M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -1.70M | -1.40M | -718.76K | -1.86M | -1.46M | 39.05K | 4.45M | 1.20M | 1.10M |
| Income Before Tax Ratio | -503.92% | -490.67% | -659.12% | -700.43% | -907.99% | -1,554.06% | -1,521.02% | -26,872.76% | -30,951.02% | -25,786.89% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -1,432.23% | -164.04% | -109.91% | -217.95% | -92.89% | 1.35% | 60.26% | 48.00% | 52.38% |
| Income Tax Expense | 850.00K | -77.00K | 45.00K | 5.00K | -111.00K | 211.00K | -651.00K | 267.00K | 74.00K | -527.00K | -22.13K | 1.96M | 378.76K | -641.75K | 714.20K | -47.29K | -190.24K | -173.90K | -168.15K | -789.40K | -19.43K | -318.03K | -318.19K | -533.46K | 31.38K | 1.57M | 200.00K | -1.10M |
| Net Income | -61.62M | -62.49M | -77.70M | -78.21M | -84.31M | -88.33M | -62.88M | -66.37M | -45.50M | -30.93M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -909.42K | -1.38M | -400.73K | -1.55M | -922.54K | 70.43K | 2.88M | 1.00M | 1.10M |
| Net Income Ratio | -510.97% | -490.06% | -659.50% | -700.47% | -906.80% | -1,557.78% | -1,505.43% | -26,981.30% | -30,951.02% | -25,354.92% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -766.71% | -161.75% | -61.28% | -180.76% | -58.86% | 2.43% | 39.00% | 40.00% | 52.38% |
| EPS | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.02 | -1.19 | 0.10 | 3.80 | 1.50 | 8.80 |
| EPS Diluted | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.01 | -1.19 | 0.10 | 3.50 | 1.20 | 6.80 |
| Weighted Avg Shares Out | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 766.80K | 776.71K | 782.19K | 761.05K | 666.67K | 549.30K |
| Weighted Avg Shares Out (Dil) | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 767.98K | 776.71K | 803.65K | 812.50K | 833.33K | 549.30K |
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and Chief Executive Officer David Patience - Chief Financial Officer Conference Call...
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024.
Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results
TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz. , Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics,...
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO David Patience - Chief Financial Officer Conference Call Participants Andrew...
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago.
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024.
Source: https://incomestatements.info
Category: Stock Reports